Evgenii A. Osmanov

N.N. Blokhin National Medical Research Centre of Oncology Ministry of Health of Russia

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 78 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Table 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li,Erin D. Henitz,Jayaprakash D. Karkera,Reyna Favis,Dana Gaffney,Alice Shapiro,Panteli Theocharous,Yusri A. Elsayed,Helgi van de Velde,Michael E. Schaffer,Evgenii A. Osmanov,Xiaonan Hong,Adriana Scheliga,Jiri Mayer,Fritz Offner,Simon Rule,Adriana Teixeira,Joanna Romejko-Jarosinska,Sven de Vos,Michael Crump,Ofer Shpilberg,Pier Luigi Zinzani,Andrew Cakana,Dixie-Lee Esseltine,George Mulligan,Deborah Ricci

openalex（2023）

Cited0Views0Bibtex

Supplementary Table 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Supplementary Methods from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Supplementary Table 4 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Supplementary Table 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Data from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier,Weimin Li,Erin D. Henitz,Jayaprakash D. Karkera,Reyna Favis,Dana Gaffney,Alice Shapiro,Panteli Theocharous,Yusri A. Elsayed,Helgi van de Velde,Michael E. Schaffer,Evgenii A. Osmanov,Xiaonan Hong,Adriana Scheliga,Jiri Mayer,Fritz Offner,Simon Rule,Adriana Teixeira,Joanna Romejko-Jarosinska,Sven de Vos,Michael Crump,Ofer Shpilberg,Pier Luigi Zinzani,Andrew Cakana,Dixie-Lee Esseltine,George Mulligan,Deborah Ricci

pubmed（2023）

Cited16Views0WOSBibtex

Supplementary Figure 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

openalex（2023）

Cited0Views0Bibtex

Biochemical Profile of Bence-Jones Type Multiple Myeloma

Nina Vasilyevna Lyubimova,Yu S Timofeev,V M Abaev,O M Votyakova,E A Osmanov,N E Kushlinskii

Kliničeskaâ laboratornaâ diagnostika（2023）

Cited1Views0WOSBibtex

Author Statistics

#Papers: 79

#Citation: 1121

H-Index: 19

G-Index: 33

Sociability: 6

Diversity: 1

Activity: 0

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn